Johnson & Johnson, Eli Lilly pause covid-19 trials for possible safety ... Washington Post - 14 Oct 2020 The trial is the second large vaccine trial to temporarily stop giving inoculations in the United States. More
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know Yahoo Finance - 05 Jun 2023 Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know ... More
Analysis: Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecast Reuters - 05 Jun 2023 Analysis: Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecast ... More
With FDA filing, Legend, J&J seek broader use of Carvykti FiercePharma - 07 Jun 2023 With FDA filing, Legend, J&J seek broader use of Carvykti ... More
J&J's multiple myeloma combo produces 96% Carvykti-like response FierceBiotech - 05 Jun 2023 J&J's multiple myeloma combo produces 96% Carvykti-like response ... More
Johnson & Johnson stock outperforms market on strong trading day MarketWatch - 05 Jun 2023 Johnson & Johnson stock outperforms market on strong trading day ... More
J&J faces new trial over talc cancer claims, amid settlement push Reuters - 31 May 2023 J&J faces new trial over talc cancer claims, amid settlement push ... More
Johnson & Johnson vaccine doses getting thrown out in the US Business Insider - 26 May 2023 Johnson & Johnson vaccine doses getting thrown out in the US ... More
J&J secures dismissal of whistleblower case over misuse of confidential info Reuters - 02 Jun 2023 J&J secures dismissal of whistleblower case over misuse of confidential info ... More
J&J Covid-19 vaccine no longer available in the US CNN - 15 May 2023 J&J Covid-19 vaccine no longer available in the US ... More
J&J's proposed talc settlement would pay $400 million to US state AGs Reuters - 16 May 2023 J&J's proposed talc settlement would pay $400 million to US state AGs ... More
Johnson & Johnson Relinquishes Top Spot To Eli Lilly (NYSE:JNJ) Seeking Alpha - 08 Jun 2023 Johnson & Johnson Relinquishes Top Spot To Eli Lilly (NYSE:JNJ) ... More
Johnson & Johnson : CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study Marketscreener.com - 05 Jun 2023 Johnson & Johnson : CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study ... More
Releases its 2022 Health for Humanity Report and We All Belong ... Johnson & Johnson - 07 Jun 2023 Releases its 2022 Health for Humanity Report and We All Belong ... ... More
Morning Medical Update: Johnson and Johnson shot no longer ... Medical Economics - 06 Jun 2023 Morning Medical Update: Johnson and Johnson shot no longer ... ... More
Johnson & Johnson Unusual Options Activity - Johnson & Johnson (NYSE:JNJ) Benzinga - 07 Jun 2023 Johnson & Johnson Unusual Options Activity - Johnson & Johnson (NYSE:JNJ) ... More
Johnson & Johnson stock rises Thursday, outperforms market MarketWatch - 08 Jun 2023 Johnson & Johnson stock rises Thursday, outperforms market ... More
CDC: Johnson & Johnson COVID-19 vaccine no longer available in ... Spectrum News NY1 - 15 May 2023 CDC: Johnson & Johnson COVID-19 vaccine no longer available in ... ... More
Talc Victims to Johnson & Johnson: There's No Escaping Science ... Business Wire - 07 Jun 2023 Talc Victims to Johnson & Johnson: There's No Escaping Science ... ... More
J&J's COVID vaccine taken by 19 MILLION Americans is pulled by ... Daily Mail - 08 Jun 2023 J&J's COVID vaccine taken by 19 MILLION Americans is pulled by ... ... More